Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovail Laboratories International SRL (BLS), the Ontario-based subsidiary of Valeant Pharmaceuticals International, has entered into an agreement to license the Canadian rights to ACZONE (dapsone) Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris from Allergan.
Subscribe to our email newsletter
Allergan will receive a CA$500,000 upfront payment from BLS which will be followed by subsequent additional payments based on net sales.
Valeant Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Valiant Pharmaceuticals CEO Michael Pearson said ACZONE Gel was a strong addition to their Canadian business.
"This compound was originally approved in 2006 and never launched into the Canadian marketplace, providing Valeant Canada with a unique opportunity to strengthen and enhance our dermatology portfolio in Canada," Pearson said.